[
CXCR4
PET/CT
Pentixafor
molecular imaging
vestibular schwannoma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
01
04
2019
accepted:
28
05
2019
entrez:
28
6
2019
pubmed:
28
6
2019
medline:
28
6
2019
Statut:
epublish
Résumé
We have recently demonstrated CXCR4 overexpression in vestibular schwannomas (VS). This study investigated the feasibility of CXCR4-directed positron emission tomography/computed tomography (PET/CT) imaging of VS using the radiolabeled chemokine ligand [
Identifiants
pubmed: 31245296
doi: 10.3389/fonc.2019.00503
pmc: PMC6581743
doi:
Types de publication
Journal Article
Langues
eng
Pagination
503Références
Nat Rev Drug Discov. 2003 Jul;2(7):581-7
pubmed: 12815382
Cancer Res. 2004 May 15;64(10):3718-24
pubmed: 15150133
J Neuropathol Exp Neurol. 2005 Dec;64(12):1080-8
pubmed: 16319718
Brain. 2008 Mar;131(Pt 3):606-15
pubmed: 17940085
Glia. 2008 May;56(7):764-74
pubmed: 18293410
Lancet. 2009 Jun 6;373(9679):1974-86
pubmed: 19476995
J Neurosurg. 2011 Feb;114(2):381-5
pubmed: 20486891
ChemMedChem. 2011 Oct 4;6(10):1789-91
pubmed: 21780290
Nat Rev Immunol. 2011 Aug 25;11(9):597-606
pubmed: 21866172
Int J Clin Exp Pathol. 2012;5(3):187-94
pubmed: 22558472
Eur J Cancer. 2013 Jan;49(1):219-30
pubmed: 22683307
Theranostics. 2013;3(1):1-2
pubmed: 23382779
Theranostics. 2013;3(1):47-75
pubmed: 23382786
Cancer Treat Rev. 2014 Aug;40(7):857-61
pubmed: 24877986
Acta Neuropathol Commun. 2014 Jul 12;2:82
pubmed: 25012216
Oncotarget. 2015 Mar 10;6(7):5022-40
pubmed: 25669980
EMBO Mol Med. 2015 Mar 03;7(4):477-87
pubmed: 25736399
J Med Genet. 2015 Oct;52(10):699-705
pubmed: 26275417
Oncotarget. 2016 Feb 23;7(8):9288-95
pubmed: 26843617
Theranostics. 2016 Jan 25;6(3):428-34
pubmed: 26909116
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Acta Neuropathol. 2016 Aug;132(2):289-307
pubmed: 27236462
Immunol Lett. 2016 Sep;177:6-15
pubmed: 27363619
Exp Hematol Oncol. 2016 Jul 16;5:19
pubmed: 27429863
Int J Mol Sci. 2016 Aug 12;17(8):
pubmed: 27529230
Clin Nucl Med. 2017 Jan;42(1):e29-e34
pubmed: 27819856
Theranostics. 2017 Jan 1;7(1):205-212
pubmed: 28042328
Theranostics. 2017 Apr 5;7(6):1489-1498
pubmed: 28529632
Tumour Biol. 2017 Jun;39(6):1010428317695528
pubmed: 28639900
Eur J Pharm Biopharm. 2017 Oct;119:310-321
pubmed: 28694161
Oncotarget. 2018 Jan 10;9(11):9940-9950
pubmed: 29515781
Am J Otol. 1997 Nov;18(6):754-60
pubmed: 9391673